This NIDA grant is for the development of new medications to treat diseases of addiction. It supports dedicated basic and/or clinical researchers to translate scientific discoveries into safe and effective pharmaceuticals or biologics. The focus is on products addressing disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. This includes developing treatments for specific symptoms like withdrawal, craving, or relapse. Proposals may also explore new formulations of existing medications or novel combinations. The program seeks to advance pharmacotherapies, including vaccines and recombinant proteins. This competitive award aims to significantly improve addiction treatment options. The selection process involves a pre-application phase, with top submissions invited for full applications.
Opportunity ID: 67974
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-DA-11-009 |
| Funding Opportunity Title: | 2011 NIDA Translational Avant-Garde Award for Medication Development for Diseases of Addiction (DP1) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 03, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jun 27, 2011 |
| Current Closing Date for Applications: | Jun 27, 2011 |
| Archive Date: | Jul 28, 2011 |
| Estimated Total Program Funding: | $1,500,000 |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments Independent school districts Private institutions of higher education Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) For profit organizations other than small businesses City or township governments Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The NIDA Translational Avant-Garde Award is designed to support dedicated and talented basic and/or clinical researchers with the vision, drive and expertise necessary to translate research discoveries into medications for the treatment of diseases of addiction. Through this funding FOA, the National Institute on Drug Abuse (NIDA) is committed to making significant advances in the development of safe and efficacious products for the treatment of disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use or abuse. These products can be pharmaceuticals (small molecules) or biologics. Biologics include medicinal products such as vaccines and recombinant therapeutic proteins created by biological processes. Applications may focus on the pharmacotherapy of one or various disorders. Applications may also focus on the specific symptoms of the disorder such as withdrawal, craving or relapse. Testing of new formulations of marketed medications that are available for other indications, or new combinations of existing medications, which may be promising candidates for the treatment of diseases of addiction is within the scope of this FOA. The 2011 Translational Avant-Garde Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-11-102. Applications will be evaluated by a group of external reviewers. Those investigators whose submissions are judged to be the most outstanding will be notified by April 26 of the opportunity to submit full applications under this FOA (DP1). The 2011 Avant-Garde awardees will be selected from this group of applicants. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-11-009.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.279 | ADOBE-FORMS-B1 | ADOBE-FORMS-B1 | PKG00030510 | May 27, 2011 | Jun 27, 2011 | View |
Package 1
Mandatory forms
67974 RR_SF424_1_2-1.2.pdf
67974 PHS398_ResearchPlan_1_3-1.3.pdf
67974 PHS398_CoverPageSupplement_1_4-1.4.pdf
67974 RR_KeyPersonExpanded_1_2-1.2.pdf
67974 RR_OtherProjectInfo_1_3-1.3.pdf
67974 PerformanceSite_1_4-1.4.pdf
Optional forms
67974 PHS_CoverLetter_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
